PHIL Evaluation in the Endovascular Treatment of Intracranial Cerebral ArterioVenous Malformation (cAVM)

NCT03341039 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2021-07-29

No results posted yet for this study

Summary

The primary objective of this study is to assess the efficacy and safety of PHIL® liquid embolic agent in endovascular embolization of cerebral arteriovenous malformations.

Conditions

  • Cerebral AV Malformation

Sponsors & Collaborators

  • ClinSearch

    collaborator OTHER
  • Microvention-Terumo, Inc.

    lead INDUSTRY

Eligibility

Min Age
28 Days
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-14
Primary Completion
2020-10-14
Completion
2020-10-14

Countries

  • Denmark
  • France
  • Spain
  • Sweden
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03341039 on ClinicalTrials.gov